Literature DB >> 16009453

World Health Organization histologic classification: an independent prognostic factor in resected thymomas.

Ottavio Rena1, Esther Papalia, Giuliano Maggi, Alberto Oliaro, Enrico Ruffini, Pierluigi Filosso, Maurizio Mancuso, Domenico Novero, Caterina Casadio.   

Abstract

The histologic classification of thymoma remained controversial since 1999, when the World Health Organization (WHO) Consensus Committee published a histologic typing system for tumours of thymus. Clinical features, postoperative relapsing rates, and survival of patients with thymoma were evaluated with reference to the WHO histologic classification, based on a series of 178 patients, submitted to surgery between 1988 and 2000. There were 21 type A, 49 type AB, 45 type B1, 50 type B2 and 13 type B3 tumours. The invasiveness of tumours was 23.8%, 51%, 73.3%, 82% and 100% for types A, AB, B1, B2 and B3 tumours, respectively. The frequency of invasion of the great vessels increased according to the tumour type in the order A (0%), AB (4%), B1 (6.6%), B2 (22%), and B3 (23%). The 10-year disease-free survival was 95%, 90%, 85%, 71% and 40% for types A, AB, B1, B2 and B3, respectively. According to the Masaoka staging system, the disease-free survival rates were 94%, 88% and 66% for stages I, II and III, respectively, at 10 years. No stage IVA thymomas reached 10 years follow-up. Overall survival at 10 years were 88% and 25% when complete and incomplete resection were considered. By multivariate analysis, Masaoka staging system, WHO histologic classification and complete resection were significant independent prognostic factors, whereas age- and sex-associated myasthenia gravis were not. The present study demonstrated the World Health Organization histologic classification a good prognostic factor, such as completeness of surgical resection and Masaoka staging system.

Entities:  

Mesh:

Year:  2005        PMID: 16009453     DOI: 10.1016/j.lungcan.2005.05.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  26 in total

1.  Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors.

Authors:  Teresa Bellissimo; Emanuele Russo; Federica Ganci; Carmen Vico; Andrea Sacconi; Flavia Longo; Domenico Vitolo; Marco Anile; Daniele Disio; Mirella Marino; Giovanni Blandino; Federico Venuta; Francesco Fazi
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

2.  The role of adjuvant chemotherapy following resection of early stage thymoma.

Authors:  Masatsugu Hamaji
Journal:  Ann Cardiothorac Surg       Date:  2016-01

3.  Co-existent Epicardial Paraganglioma and Anterior Mediastinal Thymoma.

Authors:  Matthew G Dudgeon; Sushilkumar K Sonavane; Ephraim E Parent; Andras Khoor; Mathew Thomas
Journal:  J Radiol Case Rep       Date:  2020-10-31

4.  Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.

Authors:  Seena C Aisner; Suzanne Dahlberg; Meera R Hameed; David S Ettinger; Joan H Schiller; David H Johnson; Joseph Aisner; Patrick J Loehrer
Journal:  J Thorac Oncol       Date:  2010-06       Impact factor: 15.609

5.  Thymomaptysis: unusual presentation of invasive thymoma.

Authors:  Ottavio Rena; Antonio Ramponi; Alberto Roncon; Caterina Casadio
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-01-30

6.  Prognosis and therapeutic response according to the World Health Organization histological classification in advanced thymoma.

Authors:  Tetsuzo Tagawa; Takuro Kometani; Koji Yamazaki; Tatsuro Okamoto; Hiroshi Wataya; Takashi Seto; Seiichi Fukuyama; Atsushi Osoegawa; Fumihiko Hirai; Kenji Sugio; Yukito Ichinose
Journal:  Surg Today       Date:  2011-10-04       Impact factor: 2.549

7.  18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors.

Authors:  Anish Thomas; Esther Mena; Karen Kurdziel; David Venzon; Sean Khozin; Arlene W Berman; Peter Choyke; Eva Szabo; Arun Rajan; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2013-02-04       Impact factor: 12.531

8.  Type AB thymoma is not a mixed tumor of type A and type B thymomas, but a distinct type of thymoma.

Authors:  Yukari Miki; Kana Hamada; Tadashi Yoshino; Katsuya Miyatani; Kiyoshi Takahashi
Journal:  Virchows Arch       Date:  2014-05-07       Impact factor: 4.064

9.  Surgical outcomes and reevaluation of treatment strategies for thymomas.

Authors:  Hiroyuki Ito; Haruhiko Nakayama; Masahiro Tsuboi; Yasuhiro Suga; Yoshihiro Ishikawa; Hajime Watanabe; Yoichi Kameda; Tomoyuki Yokose; Chikako Hasegawa
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

10.  Clinicopathological analysis of 241 thymic epithelial tumors-experience in the Shanghai Chest Hospital from 1997-2004.

Authors:  Lei Zhu; Jie Zhang; Alexander Marx; Christel Weiss; Wen-Tao Fang
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.